Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy

NCT02452307 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Prostate Cancer

Interventions

BIOLOGICAL: Peptide vaccine
DRUG: Montanide ISA-51
DRUG: Granulocyte macrophage colony stimulating factor (GM-CSF)
DRUG: Imiquimod
DRUG: mRNA
DRUG: Protamin
PROCEDURE: local hyperthermia

Sponsor

University Hospital Tuebingen